Scope of the Protocol

Scope of the Protocol

The Protocol covers a range of activities that involve LMOs that may have adverse effects on the conservation and sustainable use of biological diversity and health. These include:

• Transboundary movement i.e. export and import
• Transit
• Handling
• Use

Pharmaceuticals for humans which are addressed by other international agreements and/or organizations are exempted from the transboundary provisions of the Protocol by Article 5. Parties however reserve the right to subject LMOs that are pharmaceuticals for humans to Risk Assessment.

• Objective of the Protocol 
• Scope of the Protocol
• The AIA procedure in detail
• The Advance Informed Agreement Procedure

• Decision making and Risk Assessment
• Socio-Economic Considerations
• Liability and Redress for damage